Transaction creates leader in cell-based cancer immunotherapy, with complementary T-cell and NK-cell platforms focused initially on hematopoietic stem cell transplants (HSCT)
The US Food and Drug Administration (FDA) has granted ATIR101™, Kiadis Pharma’s lead investigational product for blood cancers, the Regenerative Medicine Advanced Therapy (RMAT) designation.
Kiadis Pharma is focused on leukemia. Its products address the key risks and limitations of hematopoietic stem cell transplantation, including opportunistic infections, Graft-versus-Host-Disease, cancer relapse and limited donor availability.
ATIR consists of donor lymphocytes specifically manufactured for individual patients where those T-cells from the haploidentical stem cell donor that can attack the patient are eliminated but the other donor immune cells are retained.
ATIR solves the problem of not finding a matched donor in time.
There are currently no events scheduled. View our previous events
At Kiadis Pharma, we want to keep you informed of the latest Company news, developments in our field, and let you know where you can meet us
Find out more
If you would like to know more about Kiadis Pharma, please contact us